scholarly journals Surveillance of neo-squamous epithelium after ablation of Barrett’s esophagus: is it better to use jumbo over standard biopsy forceps?

2020 ◽  
Vol 33 (7) ◽  
Author(s):  
Abhiram Duvvuri ◽  
Madhav Desai ◽  
Sachin Srinivasan ◽  
Viveksandeep Thoguluva Chandrashekar ◽  
Sreekar Vennelaganti ◽  
...  
Keyword(s):  
Barrett’S Esophagus ◽  
Lamina Propria ◽  
Barrett's Esophagus ◽  
Squamous Epithelium ◽  
Eradication Therapy ◽  
Boston Scientific ◽  
Biopsy Forceps ◽  
Squamous Mucosa ◽  
Biopsy Specimens ◽  
Adequate Tissue

Summary Background and Aims: As obtaining adequate tissue on biopsy is critical for the detection of residual and recurrent intestinal metaplasia/dysplasia in Barrett’s esophagus (BE) patients undergone Barrett’s endoscopic eradication therapy (BET), we decided to compare the adequacy of biopsy specimens using jumbo versus standard biopsy forceps. Methods: This is a two-center study of patients’ post-radiofrequency ablation of dysplastic BE. After BET, jumbo (Boston Scientific©, Radial Jaw 4, opening diameter 2.8 mm) or standard (Boston Scientific©, Radial Jaw 4, opening diameter 2.2 mm) biopsy forceps were utilized to obtain surveillance biopsies from the neo-squamous epithelium. Presence of lamina propria and proportion of squamous epithelium with partial or full thickness lamina propria was recorded by two experienced gastrointestinal pathologists who were blinded. Squamous epithelial biopsies that contained at least two-thirds of lamina propria were considered ‘adequate’. Results: In a total of 211 biopsies from 55 BE patients, 145 biopsies (29 patients, 18 males, mean age 61 years, interquartile range [IQR] 33–83) were obtained using jumbo forceps and 66 biopsies (26 patients, all males, mean age 65 years, IQR 56–76) using standard forceps biopsies. Comparing jumbo versus standard forceps, the proportion of specimens with any subepithelial lamina propria was 51.7% versus 53%, P = 0.860 and the presence of adequate subepithelial lamina propria was 17.9% versus 9.1%, P = 0.096 respectively. Conclusions: Use of jumbo forceps does not appear to have added advantage over standard forceps to obtain adequate biopsy specimens from the neo-squamous mucosa post-ablation.

1005 A Detailed Analysis of the Depth and Orientation of Neo-Squamous Biopsy Specimens in Barrett's Esophagus (BE) Patients After Endoscopic Eradication Therapy (EET)

2013 ◽  
Vol 144 (5) ◽  
pp. S-187
Author(s):  
Maria Giacchino ◽  
Sharad C. Mathur ◽  
Vijay Kanakadandi ◽  
Gokulakrishnan Balasubramanian ◽  
Neil Gupta ◽  
...  
Keyword(s):  
Detailed Analysis ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Eradication Therapy ◽  
Biopsy Specimens

Tu1534 Adequacy of Specimens of Esophageal Neo-Squamous Mucosa Using Jumbo Biopsy Forceps After Radiofrequency Ablation of Neoplastic Barrett's Esophagus

2015 ◽  
Vol 81 (5) ◽  
pp. AB499-AB500
Author(s):  
Bhairvi Jani ◽  
Diego Lim ◽  
Vijay Kanakadandi ◽  
Prashanth Vennalaganti ◽  
Neil Gupta ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Biopsy Forceps ◽  
Squamous Mucosa

Characterisation of classical and desmosomal cadherins in the neo-squamous epithelium after endoscopic ablation of Barrett's esophagus

2001 ◽  
Vol 120 (5) ◽  
pp. A416-A416
Author(s):  
C MORRIS ◽  
C TSELEPIS ◽  
R HARRISON ◽  
D GARROD ◽  
J JANKOWSKI ◽  
...  
Keyword(s):  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Squamous Epithelium ◽  
Desmosomal Cadherins ◽  
Endoscopic Ablation

scholarly journals TissueCypher Barrett’s esophagus assay impacts clinical decisions in the management of patients with Barrett’s esophagus

2021 ◽  
Vol 09 (03) ◽  
pp. E348-E355
Author(s):  
David L. Diehl ◽  
Harshit S. Khara ◽  
Nasir Akhtar ◽  
Rebecca J. Critchley-Thorne
Keyword(s):  
High Risk ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Clinical Decision Making ◽  
Eradication Therapy ◽  
Low Risk ◽  
Management Approach ◽  
Low Grade ◽  
Management Decisions ◽  
The Impact

Abstract Background and study aims The TissueCypher Barrett’s Esophagus Assay is a novel tissue biomarker test, and has been validated to predict progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) in patients with Barrett’s esophagus (BE). The aim of this study was to evaluate the impact of TissueCypher on clinical decision-making in the management of BE. Patients and methods TissueCypher was ordered for 60 patients with non-dysplastic (ND, n = 18) BE, indefinite for dysplasia (IND, n = 25), and low-grade dysplasia (LGD, n = 17). TissueCypher reports a risk class (low, intermediate or high) for progression to HGD or EAC within 5 years. The impact of the test results on BE management decisions was assessed. Results Fifty-two of 60 patients were male, mean age 65.2 ± 11.8, and 43 of 60 had long segment BE. TissueCypher results impacted 55.0 % of management decisions. In 21.7 % of patients, the test upstaged the management approach, resulting in endoscopic eradication therapy (EET) or shorter surveillance interval. The test downstaged the management approach in 33.4 % of patients, leading to surveillance rather than EET. In the subset of patients whose management plan was changed, upstaging was associated with a high-risk TissueCypher result, and downstaging was associated with a low-risk result (P < 0.0001). Conclusions TissueCypher was used as an adjunct to support a surveillance-only approach in 33.4 % of patients. Upstaging occurred in 21.7 % of patients, leading to therapeutic intervention or increased surveillance. These results indicate that the TissueCypher test may enable physicians to target EET for TissueCypher high-risk BE patients, while reducing unnecessary procedures in TissueCypher low-risk patients.

scholarly journals MicroRNA Expression Differentiates Squamous Epithelium from Barrett’s Esophagus and Esophageal Cancer

2013 ◽  
Vol 58 (11) ◽  
pp. 3178-3188 ◽  
Author(s):  
Katherine S. Garman ◽  
Kouros Owzar ◽  
Elizabeth R. Hauser ◽  
Kristen Westfall ◽  
Blair R. Anderson ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Squamous Epithelium ◽  
Microrna Expression

Mo1110 Efficacy of Multimodality Endoscopic Eradication Therapy in the Treatment of Barrett's Esophagus (BE): A Systematic Review and Meta-Analysis

2014 ◽  
Vol 146 (5) ◽  
pp. S-559
Author(s):  
Shreyas Saligram ◽  
Matthew Hall ◽  
Prashanth Vennalaganti ◽  
Stefan Seewald ◽  
Alessandro Repici ◽  
...  
Keyword(s):  
Systematic Review ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Meta Analysis ◽  
Eradication Therapy

A critical look at endoscopic eradication therapy for Barrett's esophagus: are we putting the cart before the horse?

2011 ◽  
Vol 73 (4) ◽  
pp. 659-661
Author(s):  
Neil Gupta ◽  
Irving Waxman ◽  
Prateek Sharma
Keyword(s):  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Eradication Therapy

scholarly journals Mo1275 COMPARATIVE ASSESSMENT OF THE STRUCTURAL AND FUNCTIONAL INTEGRITY OF THE NEO-SQUAMOUS EPITHELIUM FOLLOWING ENDOSCOPIC THERAPY IN BARRETT'S ESOPHAGUS: A PILOT STUDY

2020 ◽  
Vol 91 (6) ◽  
pp. AB412
Author(s):  
Lovekirat Dhaliwal ◽  
Michele L. Johnson ◽  
Ramona Lansing ◽  
Griselda Compres ◽  
Charles J. Lightdale ◽  
...  
Keyword(s):  
Pilot Study ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Squamous Epithelium ◽  
Endoscopic Therapy ◽  
Comparative Assessment ◽  
Functional Integrity

scholarly journals Dysplasia severity is associated with poor quality of life in patients with Barrett's esophagus referred for endoscopic eradication therapy

2018 ◽  
Vol 32 (1) ◽  
Author(s):  
S Han ◽  
R Yadlapati ◽  
V Simon ◽  
E Ezekwe ◽  
D S Early ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Eradication Therapy ◽  
Poor Quality
Sign in / Sign up

Export Citation Format

Share Document